GH Research (GHRS) Total Non-Current Liabilities (2023 - 2026)
GH Research (GHRS) posted quarterly Total Non-Current Liabilities of $147000.0 for Q4 2025, down 60.16% year-over-year from $369000.0 in Q4 2024, and down 32.26% quarter-over-quarter from $217000.0 in Q3 2025.
GH Research (GHRS) Total Non-Current Liabilities (2023 - 2026) Analysis & Trends
GH Research's Total Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $147000.0 for Q4 2025.
- In Q4 2025, Total Non-Current Liabilities fell 60.16% year-over-year to $147000.0; the TTM figure through Dec 2025 stood at $147000.0 (down 60.16% YoY), while the FY2025 annual figure was $147000.0, down 60.16% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $147000.0, down from $217000.0 in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $791000.0 in Q1 2023, with the low at $147000.0 in Q4 2025.
- The 3-year median for Total Non-Current Liabilities is $477500.0 (2024), against an average of $472416.7.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities fell 29.08% in 2024, then slumped 60.16% in 2025.
- GH Research's Total Non-Current Liabilities stood at $631000.0 in 2023, then sank by 41.52% to $369000.0 in 2024, then slumped by 60.16% to $147000.0 in 2025.
- Business Quant data shows GHRS's Total Non-Current Liabilities at $147000.0 in Q4 2025, $217000.0 in Q3 2025, and $283000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | 6,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6,000.00 |
| Dec 31, 2025 | 147,000.00 |
| Sep 30, 2025 | 217,000.00 |
| Jun 30, 2025 | 283,000.00 |
| Mar 31, 2025 | 322,000.00 |
| Dec 31, 2024 | 369,000.00 |
| Sep 30, 2024 | 458,000.00 |
| Jun 30, 2024 | 497,000.00 |
| Mar 31, 2024 | 561,000.00 |
| Dec 31, 2023 | 631,000.00 |
| Sep 30, 2023 | 661,000.00 |
| Jun 30, 2023 | 732,000.00 |
| Mar 31, 2023 | 791,000.00 |